Australia moves ahead with biosimilar substitution
This article was originally published in Scrip
The Australian government is pressing ahead with plans to allow pharmacist substitution of biosimilars after the Pharmaceutical Benefits Advisory Committee (PBAC) outlined the criteria that would have to be met if substitution was to take place.
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.